August 8, 2022

HQPrinceGeorge.com

Complete News World

Tribuna de La Habana

La vacuna cubana multivalente contra el pneumococci, Quimi-Vio, figure today in the first report of the Organization Mundial de la Salud (OMS) sobre inmunógenos en desarrollo para prevenir infeccións causedas por bacteria resistentes a antimicrobialos.

According to the analysis, at the moment there are 61 candidate vaccines in diverse phases of clinical study to face the diseases caused by pathogens within the list of bacteria characterized as priorities by the entity.

This way, The antillano product is included in a list distributed by the United Nations organism along with other elaborations in clinical trials designed to combat pneumococcus in countries such as the United States, the United States, Switzerland, Austria, China and Brazil..

Hace pocos meses el director general del Instituto Finlay de Vacunas, Doctor Vicente Vérez, declared that the vaccine of producción nacional está muy cerca de poder ser aplicada en niños.

As part of an intervention study, he affirmed, it was applied to small children in the province of Cienfuegos (230 kilometers to the southeast of this capital) because of which there was an important reduction in respiratory infections in that territory.

De accuerdo con declaraciones a Prensa Latina de Daniel García, director of the Laboratorio de Síntesis Química y Biomolecular de la Facultad de Química de la Universidad de La Habana, Currently se retoma la producción de Quimi-Vio y próximamente comenzará su evaluación clinica generalizada.

In reality, he said, se trata de muchas vacunas en una, pues combate las siete pas de la bacterium Streptococcus Pneumoniae, que provoca pneumonia, meningitis y sepsis en los niños..

See also  Rusia acusa a “sabotage ucranianos” del Incendio in central nuclear de Zaporiyia

(Tomado de Prensa Latina)

Other information:

Evalúan medicamento en embarazadas con anemia ferropénica